Company intelligence / Profile preview
Charsire Biotechnology
Tainan City/Xinshi District, Tainan City/Tainan Province, Taiwancharsire.com.tw ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Charsire’s lead drug BAC has completed Phase II clinical trials with promising results—79% of patients maintained or improved at week 4 without any dementia medication; this increased to 86% by week 12. No side effects were reported. The company claims BAC improves brain blood circulation, reduces inflammation, and promotes nerve cell regeneration. Phase III trials are ongoing in the US for both Alzheimer’s disease and vascular dementia
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Small molecules (notably botanical and phytotherapy-based drugs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Seeking partners for global expansion but no major partnerships disclosed yet
Beyond the preview
Go deeper on Charsire Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Charsire Biotechnology.